Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
• Institutions.
  • Address and mission.
  • Equipment/Knowhow.
  • Staff.
  • Projects.
  • Publications.
  • Advised theses.
  • Project partners.
  • Sponsors.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Diagnostic and Research Institute of Human Genetics

Project partners

Biolution Grünert & co keg, Austria

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Oridis Biomed, Forschungs- und Entwicklungs-GmbH, Elisabethstraße 84, 8010 Graz, Austria

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

European organisation for research and treatment of cancer, Avenue Mounier 83/11, 1200 Brüssel, Belgium

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

ORION Corporation, Orionintie, 02200 Espoo, Finland

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Cordeliers Research Center, France

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Institut Curie, Paris, Frankreich, 26 Rue Ulm, 750005 Paris, France

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Institut de Recherches Servier, Rue de la Republique 173, 92150 Suresnes, France

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Institut National de Sante et Recherche Medicale, France

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Institute Gustave Roussy, France

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Lapeyronie Hospital, Montpellier, France

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Université de Montpellier, 5 Boulevard Henri René - CS19044, 34967 / cedex 5 Montpellier, France

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Alacris Theranostics GmbH, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Bayer Schering Pharma AG, Müllerstraße 178, 13353 Berlin, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Boehringer Ingelheim International GmbH, Binger Straße 173, 55216 Ingelheim am Rhein, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Charite Universitätsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

GABO:MI Gesellschaft für Ablauforganisation:Milliarium mbH & Co KG, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

German Cancer Research Center, Heidelberg, Germany

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

GILUPI GmbH, Am Mühlenberg 11, 14476 Potsdam, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Heinrich Pette Institut, Hamburg, Germany

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Institute of Tumor Biology/University Medical Center Hamburg-Eppendorf, Hamburg, Germany

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Leukocare AG, Am Klopferspitz 19, 82152 Martinsried/München, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Hofgartenstrasse 8, 80539 München, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Medizinische Universität Hannover, Hannover, Germany

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Mosaiques Diagnostics & Therapeutics AG, Germany

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Siemens Healthcare Diagnostics Products GmbH, Emil-von-Behring-Strasse 76, 35041 Marburg, Germany

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

TILL Photonics, Gräfelfing, Germany

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Universität Ulm, Germany

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Universitätsklinikum Hamburg-Eppendorf, Germany

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

University of Mainz, Germany

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

National and Kapodistrian University of Athens, Greece

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

IFOM Foundation - The FIRC Institute of Molecular Oncology Foundation, Italy

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Instituto Oncologico Veneto IRCCS, Via Gattamelata , 35128 Padova, Italy

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Instituto Superiore di Sanità, Italy

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Slicon Biosystems, Via dei Lapidari, I-40129 Bologna, Italy

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Universita degli studi di Torino, Italy

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Integrated Biobank of Luxembourg Foundation, Nicolas Ernest Barblé 6, L-1210 Luxemburg, Luxembourg

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Agendia, Amsterdam, Netherlands

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Dept.Otolaryngology/Head-Neck Surgery/VU University Medical Center Amsterdam, Amsterdam, Netherlands

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Medical Center, Leiden University, Netherlands

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Netherlands Cancer Institute, Amsterdam, Netherlands

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Universitair Medisch Centrum Groningen, Netherlands

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

University Medical Center Utrecht, Netherlands

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

University of Twente, Netherlands

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

VyCAP BV, A. Rademakerstraat 41, 7425PG Deventer, Netherlands

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Oslo University Hospital, Radiumhospitalet 1, PO Box 4953 Nydalen, 0424 Oslo, Norway

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Radium Hospital Oslo, Oslo, Norway

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

TATAA Biocenter AB, Sweden

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Applied Imaging, Newcastle upon Tyne, United Kingdom

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

Cancer Research UK, United Kingdom

GENINCA - Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.01.2008-30.06.2011
   .

Eli Lilly and Company Ltd, Lilly House Priestley Road, RG24 9NL Basingstoke, United Kingdom

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

Imperial College London, London, United Kingdom

DISMAL: Molecular signatures as diagnostic and therapeutic targets for disseminated epithelial malignancies
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-6)
• Duration: 01.02.2006-30.04.2009
   .

The Chancellor, Masters and Scholars of the University of Cambridge, Cambridge, United Kingdom

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

University of Manchester, United Kingdom

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
• Project type: EN: Forschungsförderung.
• Project Leader: Speicher Michael
• MUG Research Units: Diagnostic and Research Institute of Human Genetics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2015-31.12.2019
   .

↑ Top of page / Navigation

© Med Uni Graz • Imprint